key: cord-0819037-7fd2mb94
authors: Xiong, Weixi; Lu, Lu; Zhang, Baiyang; Luo, Jianfei; Li, Weimin; He, Li; Sander, Josemir W.; Mu, Jie; Zhu, Cairong; Zhou, Dong
title: Association of consciousness impairment and mortality in people with COVID‐19
date: 2021-05-24
journal: Acta Neurol Scand
DOI: 10.1111/ane.13471
sha: 3cded4953fcdc183053784ee91fa4f29a0a036e6
doc_id: 819037
cord_uid: 7fd2mb94

BACKGROUND: To investigate the association between impairment of consciousness and risk of death in people with COVID‐19. METHODS: In this multicentre retrospective study, we enrolled people with confirmed COVID‐19 from 44 hospitals in Wuhan and Sichuan, China, between 18 January and 30 March 2020. We extracted demographics, clinical, laboratory data and consciousness level (as measured by the Glasgow Coma Scale (GCS) score) from medical records. We used Cox proportional hazards regression, structural equation modelling and survival time analysis to compare people with different progressions of impaired consciousness. RESULTS: We enrolled 1,143 people (average age 51.3 ± standard deviation 17.1‐year‐old; 50.3% males), of whom 76 died. Increased mortality risk was identified in people with GCS score between 9 and 14 (hazard ratio (HR) 46.76, p < .001) and below 9 (HR 65.86, p < .001). Pathway analysis suggested a significant direct association between consciousness level and death. Other factors, including age, oxygen saturation level and pH, had indirect associations with death mediated by GCS scores. People who developed impaired consciousness more rapidly either from symptoms onset (<10 days vs. 10–19 days, p = .025, <10 days vs. ≥20 days and 10–19 days vs. ≥20 days, <.001) or deterioration of oxygen saturation (≤2 days vs.>2 days, p = .028) had shorter survival times. CONCLUSION: Altered consciousness and its progression had a direct link with death in COVID‐19. Interactions with age, oxygen saturation level and pH suggest possible pathophysiology. Further work to confirm these findings explore prevention strategies and interventions to decrease mortality is warranted.

COVID-19, caused by a novel coronavirus (SARS-CoV-2), is a severe acute respiratory syndrome first reported in Wuhan, China, in December 2019. 1 It evolved rapidly into a global pandemic. 2 The main clinical presentations include fever, cough and shortness of breath; copious sputum production and haemoptysis and other nonspecific symptoms are also seen. 3 Critical neurological events, including impairment of consciousness and cerebrovascular accidents, have been reported. [4] [5] [6] [7] [8] [9] Impairment of consciousness is one of the most typical neurological manifestations, especially in severe, often fatal conditions. One study reported that altered consciousness at admission was a predictor for developing critical illness. 10 It has also been reported that older age, male sex and the presence of comorbidities were risk factors of higher mortality. 11, 12 Reports of the association of consciousness impairment during the illness course and outcomes are lacking, as levels and progression of altered consciousness have not been fully evaluated previously.

We aimed to investigate the associations between altered consciousness with differing time courses and death in COVID-19 and to estimate the possible causality of key clinical variables and consciousness levels on mortality.

The Ethics Board of West China Hospital, Sichuan University (approval 2020[100]) approved the study. The Committed waived the need for informed consent due to the circumstances, and retrospective nature of the study and the confirmation of full anonymization of data.

Forty-four hospitals officially designated as COVID-19 treating centres from Wuhan (Hubei Province) and Sichuan Province, China, participated. Consecutive people admitted to these hospitals who met COVID-19 diagnostic criteria to National Guidelines (Trial Version 6) 13 were enrolled. Briefly, the diagnosis was confirmed by the presence of the typical symptoms and/or characteristic features on chest imaging together with positive testing for SARS-CoV-2 RNA by real-time polymerase chain reaction (PCR).

Enrolment was between 18 January and 20 March 2020 in Sichuan and extended to 30 March in Wuhan. Among them, 223 people discharged before 18 February have been previously reviewed for seizure-related events, 14 and 741 enrolled before 20 March were reviewed for new-onset neurologic events. 15 Recruitment flow is shown in Additional file 1: Figure S1 . Those who tested negative and those with insufficient information for the evaluation of consciousness levels were excluded.

A standardized clinical report form was designed to extract data from medical records retrospectively (https://www.wjx.cn/ jq/85385 510.aspx). Demographics and related clinical features were collected. According to National Guidelines [12] , each participant's clinical condition was classified as mild, moderate, severe or critical. People with symptoms but no signs of pneumonia on imaging were considered 'mild', while those with symptoms and pneumonia signs were classified as 'moderate'. Criteria for a severe condition were respiratory distress with respiration rate (RR) ≥30/ min, resting oxygen saturation ≤93% and PaO2/FiO2 ≤300 mmHg.

People with respiratory failure, shock or other organ failure requiring intensive care unit (ICU) admission were considered critical.

Two neurologists using the Glasgow Coma Scale (GCS) independently estimated consciousness levels when altered consciousness was first mentioned in the medical notes. In cases of inconsistent scores, case notes were reviewed, and a third physician or neurologist settled the scores. For people on ventilators or with language disability, the verbal response was evaluated as '1'. 16 In those sedated, GCS scores were estimated before the introduction of sedatives. Blood oxygen saturation was recorded from the pulse oximeter if no blood gas assay was performed. Blood pH was taken from the blood gas assay. In people with GCS < 15, oxygen saturation levels and pH were recorded during disturbed consciousness or the lowest recording during admission if a corresponding oxygen level was not available. For those fully conscious throughout the admission, the lowest oxygen saturation was recorded. Outcomes were discharge, death or continued hospitalization, for those we did not have the outcome at the study end. We recorded dates of first symptoms, admission, discharge, death or last entry date if still in the hospital. The date of the first record of impaired consciousness was recorded. Time at respiratory deterioration, defined as when oxygen saturation <95% was first noted, was recorded. pathophysiology. Further work to confirm these findings explore prevention strategies and interventions to decrease mortality is warranted.

death, Glasgow Coma Scale, outcomes, risk factors

Participants were categorized into three subgroups according to GCS scores: (1) GCS = 15, fully awake without signs of impairment of consciousness; (2) between 14 and 9, with moderate impairment; and (3) <9, with severe impairment. 17 In people with mild or moderate illness, with no record of respiratory dysfunction and who never had blood gas assay, pH values were taken as 7.40. The original blood pH value was converted into the absolute value of the deviation from normal (7.35-7.45) for further analysis. For those whose pH value fell within this interval, pH was considered as '0' in this conversion. Cox proportional hazards regression modelling was used to assess the effect of GCS scores on death risk, adjusting for potential confounders (age, gender, smoking, acute complications, medical history, COVID-19 severity, oxygen saturation level and blood pH).

The proportional hazards assumption was tested using Schoenfeld residuals. People with missing survival time were excluded in the Cox regression modelling. The survival time was estimated from the time of symptom onset in all data analysis.

We used structural equation modelling to assess the interrelationships of key variables to death. Age, oxygen saturation level and pH were used as continuous variables. Parameters were estimated using the robust weighted least squares (WLSMV) method and 1,000 bootstrapping procedure was performed to obtain the bias-corrected 95% confidence interval (CI) of the indirect effect.

We excluded people with an uncertain outcome (still in hospital at study end) from the equation model. We analysed the time effect of the disturbance of consciousness in those with altered GCS scores using a Kaplan-Meier survival curve. First, we estimated progression from altered consciousness to death. Participants were divided into three groups according to the time from onset of COVID-19 symptoms to the first evidence of impaired consciousness as: (1) <10 days; (2) between 10 and 19 days and (3) ≥20 days. Next, based on the time from the first reduction of blood oxygen saturation to 95% or below to first evidence of altered consciousness, individuals were classified into two groups, ≤2 days and >2 days. Results of the log-rank test are presented to compare the survival status between the groups intuitively. Median survival time and hazard ratio were estimated.

We enrolled 1,143 individuals with an overall mortality of 6.6% (76/1143).

Additional file 2: Table S1 provides a list of participating hospitals with inclusion numbers. The average age was 51.26 years (standard deviation of 17.08 years), and 574 were men (50.3%). In Wuhan, 670 people were enrolled, and 73 (10.9%) of them died in hospital. The remaining 473 cases were from Sichuan, with 3 (0.6%) in-hospital deaths reported. The workflow of data analysis is shown in Additional file 1: Figure S1 . Eight-four reported disturbance of consciousness during admission, of whom 53 had a GCS score <9. Demographics and GCS subgroups are listed in Additional file 3: Table S2 . The most frequent comorbidities recorded were hypertension (n = 260), diabetes (n = 115) and cardiovascular disease (n = 90). Acute complications were listed in Additional file 4: Table S3 , and the commonest acute complications were electrolyte disturbance (n = 161), hepatic insufficiency (n = 138), anaemia (n = 119) and type I respiratory failure (n = 99). No individual comorbidities or complications were significant in the regression model (data not shown). Thus, they were merged into combined factors referred to as 'Acute complication' and 'Comorbidities' in the following regression analysis. Computed tomography (CT) brain scans were performed in 26 individuals, of whom eight had abnormalities; details have been previously published. 5

We included 799 participants in the multivariable Cox regression, of whom 54 died ( Table 1 ). The only significant risk factor was the GCS; both groups with GCS < 15 were significantly more at risk of death than the group with GCS 15, (p < .001). The hazard ratio was 46.76 for those with GCS between 9 and 14 and 65.86 for those with score <9, compared to those with normal GCS score. The effect of other risk factors, including age, gender, current smoker, acute complications, medical history and the severity of COVID-19, was not significant in the multivariable regression.

To assess the association between impairment of consciousness and death and potential mechanisms, we employed structural equation modelling using four key predictors: age, oxygen saturation level, pH deviation and GCS score. We excluded 144 people still in hospital at study end from this analysis. Based on the 776 participants (11, 22) days. Survival was significantly different among groups (log-rank tests: <10 days vs. 10-19 days, p = .025; <10 days vs. ≥20 days and 10-19 days vs. ≥20 days, p < .001, shown in Figure 2 ). We then evaluated whether the rapid development of consciousness alteration after the deterioration of oxygen saturation was also a significant predictive factor (shown in Figure 3 ). Five people who never had a record of an oxygen saturation <95% were excluded, the remaining 79 people were divided into two groups (1) Table 2 with significant differences in all comparisons.

We assessed levels of consciousness and their association with fatality risk. GCS scores were the only factor associated with death in the is an independent predictive factor of developing critical illness. 10 Assessing the association between consciousness and mortality is challenging, as consciousness is a dynamic process with many potential confounders. We designed a retrospective assessment and SARS-COV-2 seems to be associated with more consciousness impairment than other coronaviruses. One report concerning the Middle East respiratory syndrome CoV (MERS-CoV) identified a much higher proportion of people with confusion than in our cohort. 37 Different design and population may account for the divergent results between our study and others. 

Despite these limitations, our findings suggested a direct link between consciousness impairment and death in COVID-19. Future work assessing consciousness level and correlation with illness severity and death in larger cohorts are needed, along with optimal assessment tools and treatment to decrease COVID-19 mortality.

Not applicable.

The 

None concerning this work. with feedback from all other authors. JL, ML and LH were involved in collecting and managing data. JWS revised the manuscript and provided critical intellectual input. All authors read and approved the final manuscript.

Anonymized data will be shared by reasonable requests from any qualified investigator to the corresponding author. 

A novel coronavirus from patients with pneumonia in China

Coronavirus COVID-19 global cases by the

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Neurologic manifestations of hospitalised patients with coronavirus disease 2019 in Wuhan, China

New onset neurologic events in people with COVID-19 in 3 regions in China

Neurologic manifestations in hospitalised patients with COVID-19: the ALBACOVID registry

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Neurological manifestations of COVID-19: a systematic review and current update

Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalised patients with COVID-19

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Factors associated with COVID-19-related death using OpenSAFELY

National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocol for COVID-19

New-onset acute symptomatic seizure and risk factors in corona virus disease 2019: a retrospective multicenter study

New onset neurologic events in people with COVID-19 infection in three regions in China

The estimated verbal GCS subscore in intubated traumatic brain injury patients: is it really better?

Glasgow coma scale explained

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Introduction to mediation analysis with structural equation modeling. Shanghai Arch Psychiatry

The method of path coefficients

Structural equation model (SEM) of stroke mortality in Spanish inpatient hospital settings: the role of individual and contextual factors

Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling

The COVID-19 cytokine storm; what we know so far

Neurologic features in severe SARS-CoV-2 infection

Early post-mortem brain MRI findings in COVID-19 non-survivors

Neuropathological features of Covid-19

COVID-19 associated encephalopathy: Is there a specific EEG pattern?

De novo status epilepticus in patients with COVID-19

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Defining causality in COVID-19 and neurological disorders

Reversible encephalopathy syndrome (PRES) in a COVID-19 patient

The correlation between stroke and coronavirus disease (COVID-19): where is the evidence?

Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia

A practical method for dealing with missing Glasgow Coma Scale verbal component scores

Association of consciousness impairment and mortality in people with COVID-19